secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulgent Genetics, Inc. (FLGT)
CIK:        0001674930
Form:       8-K
Filed at:   2022-04-18T23:59:59+00:00
Accession:  0000950170-22-005754
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulgent Genetics to acquire Inform Diagnostics for $170M; prelim Q1 revenue ~$300M, above guidance
--------------------------------------------------------------------------------

- Acquisition of Inform Diagnostics for ~$170M cash; expected to close Q2 2022, funded from cash on hand.
- Preliminary Q1 total revenue ~$300M, exceeding prior guidance of $245M; core rev excl. COVID at least $22M.
- FY2022 core revenue guidance raised to ~$175M from $120M, including expected acquisition contribution.
- Acquisition adds pathology services (GI, derm, heme, etc.), 1,300 clients, 2,700 physicians, 300M+ covered lives.
- Transaction expected to contribute to core revenue and be accretive to pro forma EBITDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674930/000095017022005754/0000950170-22-005754-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674930/000095017022005754/flgt-20220416.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-005754

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer